Potential Buyouts, Stronger Pipelines, FDA Filings - Research Report on Keryx, Lilly, Baxter, Biogen Idec and Shire PR Newswire NEW YORK, March 6, 2013 NEW YORK, March 6, 2013 /PRNewswire/ -- Today, Investors Alliance announced new research reports highlighting Keryx Biopharmaceuticals (NASDAQ: KERX), Eli Lilly & Co. (NYSE: LLY), Baxter International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and Shire PLC (NASDAQ: SHPG). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Keryx Biopharmaceuticals Research Report Shares for biopharmaceutical company Keryx popped by about 12 percent following the rumor that GlaxoSmithKline may be interested in acquiring the company. Neither Keryx nor GlaxoSmithKline has issued a statement on the potential acquisition. If rumors fizzle out, however, investors for Keryx still have a reason to rejoice. Earlier this year, Keryx reported the successful results of a late-stage trial of its experimental drug for kidney disease. The drug, called Zerenex, is a treatment for hyperphosphatemia in patients with end-stage renal disease on dialysis. The company is planning to file for regulatory approval in the United States in Europe in the second quarter of 2013. The Full Research Report on Keryx Biopharmaceuticals - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/5d72_KERX] -- Eli Lilly & Co. Research Report Eli Lilly highlights its autoimmune pipeline, especially baricitinib, a treatment for patients with moderate-to-severe rheumatoid arthritis. It also has a number of other drugs currently in its Phase III clinical development pipeline, with four potential medicines for diabetes, three for cancer, two for neuroscience, three for autoimmunity and one for cardiovascular disease. At present, Lilly is adamantly defending its Erbitux drug, the FDA-approved treatment for colon cancer and head and neck tumors, against Roche Holding's complaint stating that the said drug infringes patents held by Roche's Genentech unit. Lilly states that "it has no obligation to pay royalties on the sale of Erbitux" because it did not infringe any patent. The company intends to continue strengthening its pipeline in the future. The Full Research Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/3739_LLY] -- Baxter International Inc. Research Report Investors for Baxter have a reason to celebrate after the company announced that it has submitted a biologics license application (BLA) supplement to the FDA for the approval of its hemophilia A or B drug. It is estimated that 17,000 people in the US have been diagnosed with hemophilia A or B, representing the potential market for the new drug. Furthermore, the company's acquisition of the investigational hemophilia compound from BioPharmaceuticals, Inc. is also expected to reinforce the company's hemophilia portfolio. With a strong pipeline and an increasingly growing portfolio, many expect Baxter to be valuable in the long run. The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/b301_BAX] -- Biogen Idec Inc. Research Report Shares for Biogen Idec rose following news that Bristol-Myers Squibb is interested in acquiring the company. However, neither Biogen Idec nor Bristol decided to comment. Biogen Idec recently reported Phase 3 data on the confirmed ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFC) and IX Fc fusion protein (rFIXFc) to provide against long-lasting protection from bleeding with fewer injections than required for patients with hemophilia. Many have been commenting favorably on Biogen, with analysts at Morgan Stanley increasing their price target on the company's shares from $170 to $177. Analysts at Bank of America also raised their EPS on the company's shares. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/753b_BIIB] -- Shire PLC Research Report Shares for Shire also rose following the news that it is also a potential target for Bristol. Shire has declined to comment on the issue. In mid-February, the company was also reported as an ideal takeover target for other biopharmaceutical companies including Teva. Reports suggest that Teva would be interested in Shire's ADHD drugs. Moving forward, Shire has commented that it is in "great shape," with its ADHD portfolio performing well and a promising pipeline with new growth opportunities. The Full Research Report on Shire PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/21cc_SHPG] -- Consider Investors Alliance Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks. Contact: Patricia Byers Email: press@Investors-Alliance.com Main: +1-480-745-7826 SOURCE Investors-Alliance
Potential Buyouts, Stronger Pipelines, FDA Filings - Research Report on Keryx, Lilly, Baxter, Biogen Idec and Shire
Press spacebar to pause and continue. Press esc to stop.